Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI technique could sharpen radiation for deadly brain tumors

NCT ID NCT05500612

Knowledge-focused Sponsor: University of Sydney Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether special MRI scans can identify low-oxygen (hypoxic) areas in glioblastoma, an aggressive brain cancer. Researchers will compare these scans with a standard PET imaging method in 20 participants. The goal is to see if MRI can reliably guide radiation therapy to the most dangerous parts of the tumor, potentially making treatment more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to more targeted radiation therapy for glioblastoma, potentially improving treatment outcomes.
What could go wrong
This is a very small early-stage study (20 participants) focused on imaging, not treatment. It may not lead to direct patient benefits or change clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Histopathological diagnosis of a high grade glioma / glioblastoma multiforme

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Suspected high-grade glioma (HGG) / glioblastoma multiforme (WHO grade IV) at initial radiological examination * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 * Available for scanning on two separate days Exclusion Criteria: * Women lactating, pregnant or of childbearing potential who are not willing to avoid pregnancy during the study * Patients with a history of severe renal disease(s) (eGFR \<20) that cannot tolerate gadolinium chelate contrast agents. * Geographically remote patients unable to agree to imaging schedule * Patients who have received anti - vascular endothelial growth factor (anti-VEGF) monoclonal antibody therapy the 3 months prior to recruitment * Patients with a history of psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study. * Patients with significant cardiac or pulmonary disease including cardiac arrythmias or Chronic Obstructive Pulmonary Disease (COPD) that are unable to tolerate high flow O2 for oxygen contrast. * Patients taking carbonic anhydrase inhibitors (Acetazolamide) * History of glaucoma * Any implant, foreign body, 3 Tesla (3T) MRI incompatible device, or other contraindication to MRI imaging.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma multiforme are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioblastoma multiforme

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • North Shore Private Hospital

    NOT_YET_RECRUITING

    St Leonards, New South Wales, 2065, Australia

  • Royal North Shore Hospital

    RECRUITING

    St Leonards, New South Wales, 2065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.